<SEC-DOCUMENT>0000875045-24-000012.txt : 20240424
<SEC-HEADER>0000875045-24-000012.hdr.sgml : 20240424
<ACCEPTANCE-DATETIME>20240424070257
ACCESSION NUMBER:		0000875045-24-000012
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20240424
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240424
DATE AS OF CHANGE:		20240424

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOGEN INC.
		CENTRAL INDEX KEY:			0000875045
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				330112644
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19311
		FILM NUMBER:		24866697

	BUSINESS ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		7814642000

	MAIL ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC.
		DATE OF NAME CHANGE:	20070427

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC
		DATE OF NAME CHANGE:	20031112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IDEC PHARMACEUTICALS CORP / DE
		DATE OF NAME CHANGE:	19970530
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>biib-20240424.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:31ab756c-268d-47bf-960f-40deff5d63b1,g:9ac60f70-3d0b-4dd0-82a8-03278455582b,d:2db446ffb016466f82effc0a71a1cd31-->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>biib-20240424</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-21">0000875045</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-22">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="biib-20240424.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-24</xbrli:startDate><xbrli:endDate>2024-04-24</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i2db446ffb016466f82effc0a71a1cd31_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric> </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported):  </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">April 24, 2024</ix:nonNumeric></span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">BIOGEN INC.</ix:nonNumeric></span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter) </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.590%"><tr><td style="width:1.0%"/><td style="width:37.076%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.811%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.813%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">0-19311</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">33-0112644</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(IRS Employer Identification No.)</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">225 Binney Street</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Cambridge</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">Massachusetts</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">02142</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Address of principal executive offices; Zip Code)</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code:  </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">617</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">679-2000</ix:nonNumeric></span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Former name or former address, if changed since last report.)</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:31.744%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.744%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.746%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, $0.0005 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">BIIB</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-20">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9744;</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i2db446ffb016466f82effc0a71a1cd31_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:14pt"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item 2.02&#160;&#160;&#160;&#160;Results of Operations and Financial Condition. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April&#160;24, 2024, Biogen Inc. issued a press release announcing its results of operations and financial condition for the first quarter ended March 31, 2024. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The press release is being furnished pursuant to Item 2.02 of this Current Report on Form 8-K and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that Section, nor shall such document be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.</span></div><div style="margin-top:14pt"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item 9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span></div><div style="text-align:justify;text-indent:33.75pt"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;Exhibits</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits listed below are furnished as part of this Current Report on Form 8-K.</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:18.401%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:79.399%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit991-q12024pressrele.htm">Biogen's press release dated April 24, 2024</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.807%"><tr><td style="width:1.0%"/><td style="width:7.156%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:90.644%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">BIOGEN INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;/s/ Wendell Taylor </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wendell Taylor</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Secretary</span></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                              </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date:  April&#160;24, 2024</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit991-q12024pressrele.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i805a86fcdf724b4d9a162b5e727cb428_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><img alt="newbiogenlogo.jpg" src="newbiogenlogo.jpg" style="height:47px;margin-bottom:5pt;vertical-align:text-bottom;width:145px"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> Press Release</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cambridge, Mass. &#8211; Apr. 24, 2024</font></div><div><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Biogen reports first quarter 2024 GAAP EPS growth of 1% and Non-GAAP EPS growth of 8% </font></div><div style="margin-top:14pt"><font style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:115%">First quarter revenue $2.3 billion&#59; GAAP diluted EPS $2.70&#59; Non-GAAP diluted EPS $3.67</font></div><div><font><br></font></div><div><font style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:112%">First quarter product revenue decreased 3% and total revenue decreased 7%, while GAAP operating income grew 10% and Non-GAAP operating income grew 24%&#59; meaningful improvement in both gross and operating margins due to Fit for Growth program and R&#38;D prioritization</font></div><div style="margin-top:14pt"><font style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:112%">LEQEMBI launch uptake accelerated with first quarter global in-market sales of approximately $19 million, nearly triple the fourth quarter of 2023, and patients on therapy increasing nearly 2.5 times since the end of 2023. Significant increase in new patient starts observed in March which contributed over 20% of cumulative patients now on LEQEMBI.</font></div><div><font><br></font></div><div><font style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:112%">SKYCLARYS first quarter global revenue of $78 million with patient identification and access progressing in the U.S. and E.U. launch now successfully underway</font></div><div style="margin-top:14pt"><font style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:115%">ZURZUVAE launch shows encouraging early trends</font></div><div><font><br></font></div><div><font style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:112%">SPINRAZA grew 1% in the U.S. with timing of shipments and increased competition impacting first quarter revenue comparisons outside the U.S.</font></div><div><font><br></font></div><div><font style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Reaffirming full year 2024 financial guidance&#58; Non-GAAP EPS of $15.00 to $16.00, representing EPS growth of approximately 5% versus 2023 at the mid-point</font></div><div style="margin-top:5pt;padding-left:27pt;text-indent:-18pt"><font style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:11.4pt">Continue to expect total revenue to decline by a low- to mid-single digit percentage vs. 2023 and expect core pharmaceutical revenue (product revenue + LEQEMBI) to be flat vs. 2023</font></div><div style="margin-top:5pt;padding-left:27pt;text-indent:-18pt"><font style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:11.4pt">Continue to expect operating income to grow low-double digit percentage vs. 2023 with expected mid-single digit percentage point operating margin improvement</font></div><div style="margin-top:14pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Biogen Inc. (NASDAQ&#58; BIIB) today reported first quarter 2024 financial results.  </font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Commenting on the quarter, President and Chief Executive Officer Christopher A. Viehbacher said&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;We are starting 2024 with an increase in earnings per share and solid execution across our new product launches along with the realization of meaningful cost savings and margin improvement. We see momentum building at a steady pace for LEQEMBI. In particular, we were encouraged that LEQEMBI in-market revenue for the first quarter nearly tripled sequentially and we saw a significant build in month-to-month new patient starts in the first quarter. As the launch progresses and infrastructure develops, we continue to believe in the potential longer-term commercial opportunity in Alzheimer&#8217;s disease. In rare disease, the U.S. launch of SKYCLARYS is advancing well and with the E.U. launch underway, we are beginning to realize the value of the Reata transaction. The uptake of ZURZUVAE in postpartum depression and QALSODY in SOD-1 ALS, two areas of significant unmet need, has also been encouraging. With a renewed culture focused on purpose and performance, we are advancing toward our goal of returning to sustainable growth while creating enhanced value for patients and our shareholders.&#34;</font></div><div style="margin-top:15pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Financial Highlights</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Q1 '24</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Q1 '23</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#9651;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Wingdings 3',sans-serif;font-size:10pt;font-weight:700;line-height:100%">r</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> (CC</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Revenue (in millions)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2,290</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2,463</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GAAP diluted EPS</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.70</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.67</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP diluted EPS</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.67</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.40</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#447260;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Note&#58; Percent changes represented as favorable&#47;(unfavorable) versus the prior year period.</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">*</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> Percentage changes in revenue growth at constant currency (CC) are presented excluding the impact of changes in foreign currency exchange rates and hedging gains or losses. Foreign currency revenue values are converted into U.S. Dollars using the exchange rates from the end of the previous calendar year.                                                                                                  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A reconciliation of GAAP to Non-GAAP financial measures can be found in Table 4 at the end of this news release.</font></div><div style="margin-top:15pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Revenue Summary</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Q1 '24</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Q1 '23</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#9651;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Wingdings 3',sans-serif;font-size:10pt;font-weight:700;line-height:100%">r</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> (CC</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Multiple sclerosis (MS) product revenue</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,076</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,125</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rare disease revenue</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$424</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$443</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biosimilars revenue</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$197</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$192</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other product revenue</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$15</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenue</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,712</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,763</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from anti-CD20 therapeutic programs</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$394</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$399</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract manufacturing, royalty and other revenue</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$185</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$300</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenue</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2,290</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$2,463</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7)%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Note&#58; Percent changes represented as favorable&#47;(unfavorable) versus the prior year period. Numbers may not foot or recalculate due to rounding.</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> Multiple sclerosis includes TECFIDERA&#174;, VUMERITY&#174;, AVONEX&#174;, PLEGRIDY&#174;, TYSABRI&#174; and FAMPYRA&#8482;.</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> Rare disease includes SPINRAZA&#174;, QALSODY&#174; and SKYCLARYS&#174;.</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.85pt;font-weight:400;line-height:107%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:107%"> Other includes ADUHELM&#174;, FUMADERM&#8482; and ZURZUVAE&#8482;. </font></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><font style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:10pt">First quarter 2024 ZURZUVAE revenue was approximately $12 million.</font></div><div style="margin-top:15pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Expense Summary</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.547%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Q1 '24</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Q1 '23</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#9651;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GAAP cost of sales</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$542</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$663</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">% of Total Revenue</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">24%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">27%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP cost of sales</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$663</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">% of Total Revenue</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">22%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">27%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GAAP R&#38;D expense</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$453</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$571</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP R&#38;D expense</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$447</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$571</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GAAP SG&#38;A expense</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$582</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$605</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP SG&#38;A expense</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$569</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$603</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Note&#58; Percent changes represented as favorable&#47;(unfavorable) versus the prior year period</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">*</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> Excluding amortization and impairment of acquired intangible assets</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:10.67pt">There were no idle capacity charges in the first quarter of 2024. First quarter 2023 GAAP and Non-GAAP cost of sales includes approximately $45&#160;million of idle capacity charges. The decrease in first quarter 2024 GAAP and Non-GAAP cost of sales as a percentage of total revenue was driven primarily by product mix, particularly the year-over-year increase in revenue from new product launches and decrease in contract manufacturing revenue, as well as less idle capacity charges.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:10.67pt">In the first quarter 2024 as compared to the first quarter of 2023, the decrease in GAAP R&#38;D and SG&#38;A expense of approximately $118 million and $24 million, respectively, and the decrease in Non-GAAP R&#38;D and SG&#38;A expense of approximately $124 million and $33 million, respectively, was primarily due to savings achieved from our Fit for Growth and R&#38;D portfolio prioritization initiatives. First quarter 2023 GAAP and Non-GAAP SG&#38;A expense includes approximately $31 million related to </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#447260;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:112%">the termination of the co-promotion agreement with Eisai for Biogen&#8217;s multiple sclerosis products in Japan.</font></div><div style="margin-top:15pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Other Financial Highlights</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:11.4pt">First quarter 2024 GAAP and Non-GAAP collaboration profit sharing was a net expense of $66&#160;million, which includes $61&#160;million related to Biogen&#8217;s collaboration with Samsung Bioepis, and $5&#160;million to Sage Therapeutics related to the commercialization of ZURZUVAE in the U.S. </font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:11.4pt">First quarter 2024 GAAP other expense was $94&#160;million, primarily driven by net interest expense and net unrealized losses on strategic equity investments of $31 million. First quarter 2024 Non-GAAP other expense was $63&#160;million, primarily driven by net interest expense.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:11.4pt">First quarter 2024 GAAP and Non-GAAP effective tax rates were 15.4% and 15.9%, respectively. First quarter 2023 GAAP and Non-GAAP effective tax rates were 11.6% and 13.5%, respectively, and benefited from the resolution of an uncertain tax matter and higher non-cash tax benefits from changes in the value of our equity investments.</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Financial Position</font></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:11.4pt">First quarter 2024 net cash flow from operations was $553&#160;million. Capital expenditures were $46&#160;million, and free cash flow, defined as net cash flow from operations less capital expenditures, was $507&#160;million.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:11.4pt">As of March 31, 2024, Biogen had cash, cash equivalents, and marketable securities totaling approximately $1.1 billion and approximately $6.5 billion in total debt, resulting in net debt of approximately $5.5 billion. As of March 31, 2024 $750 million of the 2023 Term Loan which was put in place at the time of the Reata acquisition had been repaid, with the remaining $250 million expected to be repaid during the second quarter of 2024. </font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:11.4pt">Subsequent to the end of the first quarter of 2024, Biogen received its scheduled installment payment of approximately $437 million from Samsung BioLogics related to Biogen's sale of its JV equity stake in Samsung Bioepis.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:11.4pt">No shares of the Company&#8217;s common stock were repurchased in the first quarter of 2024. As of March 31, 2024, there was $2.1&#160;billion remaining under the share repurchase program authorized in October 2020.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:11.4pt">For the first quarter of 2024 the Company&#8217;s weighted average diluted shares were 146 million.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Full Year 2024 Financial Guidance</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:112%">For the full year 2024, Biogen continues to expect a Non-GAAP diluted EPS guidance range as follows&#58;</font></div><div style="margin-top:9pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.929%"><tr><td style="width:1.0%"></td><td style="width:30.404%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:66.583%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Reaffirmed Full Year 2024 Guidance</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt dashed #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Non-GAAP diluted EPS</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:0.5pt dashed #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:112%">$15.00 to $16.00</font></div><div style="margin-top:3pt;text-align:center"><font style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Reflecting growth of &#126;5% at the mid-point</font><font style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:7.15pt;font-weight:400;line-height:112%;position:relative;top:-3.85pt;vertical-align:baseline">*</font></div></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">*</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Versus reported full year 2023</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:112%">While total revenue is expected to decline by a low- to mid-single digit percentage, Biogen continues to expect core pharmaceutical revenue, defined as product revenue plus Biogen's 50% share of net LEQEMBI product revenue and cost of sales, including royalties, to be relatively flat for 2024 compared to 2023 as further declines in multiple sclerosis product revenue are expected to be offset by increases in revenue from new product launches. </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#447260;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Biogen continues to expect an improvement in the cost of sales as a percentage of total revenue for 2024 compared to 2023 driven by product mix and significantly lower idle capacity charges.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:115%">For 2024 compared to 2023, Biogen continues to expect operating income to grow at a low-double digit percentage. This is expected to be driven by improved cost of sales as a percentage of revenue, as well as lower operating expenses as a result of the Company's Fit for Growth program. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This guidance also assumes that foreign exchange rates as of April 19, 2024, will remain in effect for the remainder of the year, net of hedging activities. Other modeling considerations will be provided on the conference call and webcast.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This financial guidance does not include any impact from potential acquisitions or large business development transactions or pending and future litigation, as all are hard to predict, or any impact of potential tax or healthcare reform. Biogen may incur charges, realize gains or losses, or experience other events or circumstances in 2024 that could cause any of these assumptions to change and&#47;or actual results to vary from this financial guidance.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Biogen does not provide guidance for GAAP reported financial measures (other than revenue) or a reconciliation of forward-looking Non-GAAP financial measures to the most directly comparable GAAP reported financial measures because the Company is unable to predict with reasonable certainty the financial impact of items such as the transaction, integration, and certain other costs related to acquisitions or large business development transactions&#59; unusual gains and losses&#59; potential future asset impairments&#59; gains and losses from our equity security investments&#59; and the ultimate outcome of pending or future significant litigation without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. For the same reasons, the Company is unable to address the significance of the unavailable information, which could be material to future results.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Conference Call and Webcast </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The Company&#8217;s earnings conference call for the first quarter will be broadcast via the internet at 8&#58;30 a.m. ET on April&#160;24, 2024 and will be accessible through the Investors section of Biogen&#8217;s website, www.biogen.com. Supplemental information in the form of a slide presentation is also accessible at the same location on the internet and will be subsequently available on the website for at least 90 days.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:115%">About Biogen</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient&#8217;s lives and to create value for shareholders and our communities.</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:112%">We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:112%">We routinely post information that may be important to investors on our website at </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:112%">www.biogen.com. Follow us on social media - Facebook, LinkedIn, X, YouTube.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Biogen Safe Harbor </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This press release contains forward-looking statements, relating to&#58; our strategy and plans&#59; potential of, and expectations for, our commercial business and pipeline programs&#59; capital allocation and investment strategy&#59; clinical development programs, clinical trials, and data readouts and presentations&#59; regulatory discussions, submissions, filings, and approvals&#59; the potential benefits, safety, and efficacy of our and our collaboration partners&#8217; products and investigational therapies&#59; the anticipated benefits and potential of investments, optimization of the cost structure including our &#34;Fit for Growth&#34; program, actions to improve risk profile and productivity of R&#38;D pipeline, collaborations, and business development activities&#59; our future financial and operating results&#59; 2024 financial guidance. These forward-looking statements may be accompanied by such words as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#447260;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;forecast,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;possible,&#8221; &#8220;prospect,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:112%">These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including&#58; our dependence on sales from our products&#59; uncertainty of long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products&#59; failure to compete effectively&#59; failure to successfully execute or realize the anticipated benefits of our strategic and growth initiatives&#59; difficulties in obtaining and maintaining adequate coverage, pricing, and reimbursement for our products&#59; our dependence on collaborators and other third parties for the development, regulatory approval, and commercialization of products and other aspects of our business, which are outside of our full control&#59; risks associated with current and potential future healthcare reforms&#59; risks related to commercialization of biosimilars&#59; failure to obtain, protect, and enforce our data, intellectual property, and other proprietary rights and the risks and uncertainties relating to intellectual property claims and challenges&#59; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications&#59; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates&#59; the occurrence of adverse safety events, restrictions on use with our products, or product liability claims&#59; risks relating to technology failures or breaches&#59; problems with our manufacturing processes&#59; risks relating to management, personnel and other organizational changes, including attracting and retaining personnel&#59; failure to comply with legal and regulatory requirements&#59; the risks of doing business internationally, including currency exchange rate fluctuations&#59; risks relating to investment in our manufacturing capacity&#59; risks relating to the distribution and sale by third parties of counterfeit or unfit versions of our products&#59; risks relating to the use of social media and artificial intelligence based software for our business&#59; results of operations, and financial condition&#59; fluctuations in our operating results&#59; risks related to investment in properties&#59; risks relating to access to capital and credit markets&#59; risks related to indebtedness&#59; the market, interest, and credit risks associated with our investment portfolio&#59; risks relating to share repurchase programs&#59; change in control provisions in certain of our collaboration agreements&#59; fluctuations in our effective tax rate&#59; environmental risks&#59; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:112%">These statements speak only as of the date of this press release. We do not undertake any obligation to publicly update any forward-looking statements.</font></div><div style="margin-top:6pt"><font><br></font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:115%">###</font></div><div style="margin-top:6pt"><font><br></font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"></td><td style="width:50.846%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.954%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:115%">MEDIA CONTACT&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><font style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:115%">INVESTOR CONTACT&#58;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Biogen</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Biogen</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Jack Cox</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Chuck Triano</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Tel&#58; +1 781-464-3260</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Tel&#58; +1 781-464-2442 </font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:112%">public.affairs&#64;biogen.com</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:112%">IR&#64;biogen.com</font></div></td></tr></table></div><div style="margin-top:6pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#447260;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5</font></div></div></div><div id="i805a86fcdf724b4d9a162b5e727cb428_4"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div id="i805a86fcdf724b4d9a162b5e727cb428_7"></div><div style="text-align:center"><font style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TABLE 1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="text-align:center"><font style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENT OF INCOME</font></div><div style="text-align:center"><font style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(unaudited, in millions, except per share amounts)</font></div><div style="text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product, net</font></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,711.9&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,763.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue from anti-CD20 therapeutic programs</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">394.0&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">399.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract manufacturing, royalty and other revenue</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184.6&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,290.5&#160;</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,463.0&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost and expense&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales, excluding amortization and impairment of acquired intangible assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">542.2&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">662.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">452.9&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">570.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">581.5&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">605.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization and impairment of acquired intangible assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.3&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Collaboration profit sharing&#47;(loss reimbursement)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65.6&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring charges</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.5&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (income) expense, net</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93.7&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cost and expense</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,825.7&#160;</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,024.7&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income tax expense and equity in loss of investee, net of tax</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">464.8&#160;</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">438.3&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax (benefit) expense</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71.4&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">393.4&#160;</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">387.6&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net&#160;income (loss) attributable to noncontrolling interests, net&#160;of&#160;tax</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.3)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Biogen Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">393.4&#160;</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">387.9&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic earnings per share attributable to Biogen Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.71&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.69&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted earnings per share attributable to Biogen Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.70&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.67&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares used in calculating&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic earnings share attributable to Biogen Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145.2&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted earnings per share attributable to Biogen Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145.9&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#447260;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6</font></div></div></div><div id="i805a86fcdf724b4d9a162b5e727cb428_10"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TABLE 2</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="text-align:center"><font style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</font></div><div style="text-align:center"><font style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(unaudited, in millions)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:51.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.451%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.049%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of March 31, 2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2023</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,074.4&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,049.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,604.5&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,664.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due from anti-CD20 therapeutic programs, net</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">395.2&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">435.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,516.8&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,527.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,165.3&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,182.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,756.2&#160;</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,859.3&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, net</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,275.3&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,309.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">428.1&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">420.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets, net</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,284.7&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,363.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,227.4&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,219.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax asset</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">898.3&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">928.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments and other assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">697.6&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">745.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TOTAL ASSETS</font></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,567.6&#160;</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,844.8&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of term loan</font></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">250.0&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taxes payable</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">231.2&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">257.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">387.0&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">403.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,354.6&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,623.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Total current liabilities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,222.8&#160;</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,434.3&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Notes payable and term loan</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,290.1&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,788.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liability</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">658.1&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">641.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">406.5&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">777.1&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">781.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,213.0&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,799.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TOTAL LIABILITIES AND EQUITY</font></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,567.6&#160;</font></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,844.8&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#447260;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">7</font></div></div></div><div id="i805a86fcdf724b4d9a162b5e727cb428_13"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TABLE 3</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="text-align:center"><font style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PRODUCT REVENUE &#38; TOTAL REVENUE</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(unaudited, in millions)</font></div><div><font style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Product Revenue</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.550%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br>States</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br>World</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br>States</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br>World</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis (MS)&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TECFIDERA</font></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.7&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">210.6&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">254.3&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">199.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">274.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">VUMERITY</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105.9&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.6&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.5&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">108.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Fumarate</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149.6&#160;</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232.2&#160;</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">381.8&#160;</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">168.2&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">214.5&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">382.7&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVONEX</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111.2&#160;</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67.3&#160;</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178.5&#160;</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102.6&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.8&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">172.4&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PLEGRIDY</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.6&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36.5&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65.1&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Interferon</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139.8&#160;</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103.8&#160;</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">243.6&#160;</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.5&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113.1&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">245.6&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">213.8&#160;</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">217.5&#160;</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">431.3&#160;</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">245.4&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">227.4&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">472.8&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.2&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.2&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal&#58; MS</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">503.2&#160;</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">572.7&#160;</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,075.9&#160;</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">546.1&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">579.1&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,125.2&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rare Disease&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148.5&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">192.8&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">341.3&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">296.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">443.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">QALSODY</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.4&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.6&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SKYCLARYS</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73.0&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.0&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.0&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal&#58; Rare Disease</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">225.9&#160;</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">198.0&#160;</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">423.9&#160;</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146.7&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">296.6&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">443.3&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118.7&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118.7&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.8&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.8&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.8&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.8&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BYOOVIZ</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.7&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.9&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal&#58; Biosimilars</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.7&#160;</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">193.2&#160;</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">196.9&#160;</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.2&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">184.2&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">192.4&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.3&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.9&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.2&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue</font></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">746.1&#160;</font></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">965.8&#160;</font></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,711.9&#160;</font></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">701.4&#160;</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,061.9&#160;</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,763.3&#160;</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> QALSODY became commercially available in the U.S. during the second quarter of 2023.</font></div><div style="margin-top:1pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> SKYCLARYS was obtained as part of our acquisition of Reata in September 2023. SKYCLARYS became commercially available in the U.S. during the second quarter of 2023 and we began recognizing revenue from SKYCLARYS in the U.S. during the fourth quarter of 2023, subsequent to our acquisition. SKYCLARYS was approved and became commercially available in the E.U. during the first quarter of 2024.</font></div><div style="margin-top:1pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> BYOOVIZ became commercially available in certain international markets in 2023.</font></div><div style="margin-top:1pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Other includes FUMADERM, ADUHELM and ZURZUVAE, which became commercially available in the U.S. during the fourth quarter of 2023.</font></div><div><font><br></font></div><div><font style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Total Revenue</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenue</font></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,711.9&#160;</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,763.3&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OCREVUS royalties</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">302.7&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">283.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RITUXAN&#47;GAZYVA</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#47;LUNSUMIO&#8482; revenue</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87.1&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenues from anti-CD20 programs</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract manufacturing, royalty and other revenue</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">184.6&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">300.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</font></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,290.5&#160;</font></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,463.0&#160;</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#447260;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">8</font></div></div></div><div id="i805a86fcdf724b4d9a162b5e727cb428_16"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TABLE 4</font></div><div id="i805a86fcdf724b4d9a162b5e727cb428_19"></div><div style="margin-top:15pt;text-align:center"><font style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="text-align:center"><font style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GAAP TO NON-GAAP RECONCILIATION</font></div><div style="text-align:center"><font style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">OPERATING EXPENSE, OTHER (INCOME) EXPENSE, NET, AND INCOME TAX</font></div><div style="text-align:center"><font style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(unaudited, in millions, except effective tax rate)</font></div><div style="margin-top:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We supplement our GAAP consolidated financial statements and GAAP financial measures with other financial measures, such as adjusted net income, adjusted diluted earnings per share, revenue growth at constant currency, which excludes the impact of changes in foreign exchange rates and hedging gains or losses, and free cash flow, which is defined as net cash flow from operations less capital expenditures. We believe that these and other Non-GAAP financial measures provide additional insight into the ongoing economics of our business and reflect how we manage our business internally, set operational goals and form the basis of our management incentive programs. Non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP.</font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost of Sales&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cost of sales, GAAP</font></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">542.2&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">662.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less&#58; amortization of Reata inventory step-up</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.2&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cost of sales, Non-GAAP</font></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500.0&#160;</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">662.8&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Research and Development Expense&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total research and development expense, GAAP</font></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">452.9&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">570.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less&#58; restructuring charges and other cost saving initiatives</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.6&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less&#58; other</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.4)</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total research and development expense, Non-GAAP</font></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">446.7&#160;</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">570.5&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Selling, General and Administrative Expense&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total selling, general and administrative, GAAP</font></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">581.5&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">605.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less&#58; acquisition-related transaction and integration costs</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less&#58; restructuring charges and other cost saving initiatives</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.6&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less&#58; other</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total selling, general and administrative, Non-GAAP</font></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">569.4&#160;</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">602.6&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization and Impairment of Acquired Intangible Assets&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total amortization and impairment of acquired intangible assets, GAAP</font></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.3&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less&#58; amortization of acquired intangible assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68.8&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total amortization and impairment of acquired intangible assets, Non-GAAP</font></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.5&#160;</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.6&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other (Income) Expense, net&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other (income) expense, net, GAAP</font></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93.7&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less&#58; (gain) loss on equity security investments</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.7&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less&#58; other</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other (income) expense, net, Non-GAAP</font></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63.0&#160;</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.7)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Tax (Benefit) Expense&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total income tax expense, GAAP</font></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71.4&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less&#58; income tax effect related to Non-GAAP reconciling items</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29.9)</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26.3)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total income tax expense, Non-GAAP</font></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.3&#160;</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77.0&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Tax Rate&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total effective tax rate, GAAP</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.4&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less&#58; impact of GAAP to Non-GAAP adjustments</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.9)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total effective tax rate, Non-GAAP</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.9&#160;</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.5&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#447260;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt;text-align:center;text-indent:36pt"><font style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TABLE 4 (continued)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="text-align:center"><font style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GAAP TO NON-GAAP RECONCILIATION</font></div><div style="text-align:center"><font style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NET INCOME ATTRIBUTABLE TO BIOGEN INC. &#38; DILUTED EPS</font></div><div style="text-align:center"><font style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(unaudited, in millions, except per share amounts)</font></div><div style="text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Income (loss) Attributable to Biogen Inc.&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total net income (loss) attributable to Biogen Inc., GAAP</font></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">393.4&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">387.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plus&#58; amortization of Reata inventory step-up</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.2&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plus&#58; acquisition-related transaction and integration costs</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plus&#58; amortization of acquired intangible assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68.8&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plus&#58; restructuring charges and other cost saving initiatives</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.7&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plus&#58; (gain) loss on equity security investments</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.7&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plus&#58; income tax effect related to Non-GAAP reconciling items</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29.9)</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26.3)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plus&#58; other</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total net income (loss) attributable to Biogen Inc., Non-GAAP</font></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">535.0&#160;</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">493.4&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diluted Earnings Per Share&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total diluted earnings (loss) per share, GAAP</font></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.70&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.67&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Less) Plus&#58; adjustments to GAAP net income attributable to Biogen Inc. (as detailed above)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.97&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.73&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total diluted earnings per share, Non-GAAP</font></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.67&#160;</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.40&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#447260;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10</font></div></div></div><div id="i805a86fcdf724b4d9a162b5e727cb428_22"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt;text-align:center"><font style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TABLE 4 (continued)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="text-align:center"><font style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GAAP TO NON-GAAP RECONCILIATION&#58; REVENUE GROWTH AT CONSTANT CURRENCY</font></div><div style="text-align:center"><font style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(unaudited)</font></div><div style="margin-top:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Percentage changes in revenue growth at constant currency are presented excluding the impact of changes in foreign currency exchange rates and hedging gains or losses. Foreign currency revenue values are converted into U.S. Dollars using the exchange rates from the end of the previous calendar year.</font></div><div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Q1 2024<br>vs.<br>Q1 2023</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Revenue&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue change, as reported</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7.0)</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less&#58; impact of foreign currency translation and hedging gains &#47; losses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue change at constant currency</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7.0)</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Product Revenue&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue change, as reported</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.9)</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less&#58; impact of foreign currency translation and hedging gains &#47; losses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.3)</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue change at constant currency</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.6)</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total MS Product Revenue&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue change, as reported</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.4)</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less&#58; impact of foreign currency translation and hedging gains &#47; losses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue change at constant currency</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.2)</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Rare Disease Revenue</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue change, as reported</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.4)</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less&#58; impact of foreign currency translation and hedging gains &#47; losses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.8)</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue change at constant currency</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.6)</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total SPINRAZA Rest of World Revenue</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue change, as reported</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35.0)</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less&#58; impact of foreign currency translation and hedging gains &#47; losses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue change at constant currency</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35.0)</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Biosimilars Product Revenue&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue change, as reported</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.3&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less&#58; impact of foreign currency translation and hedging gains &#47; losses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue change at constant currency</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.4&#160;</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Other Product Revenue (FUMADERM, ADUHELM and ZURZUVAE)&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue change, as reported</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">538.4&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less&#58; impact of foreign currency translation and hedging gains &#47; losses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.2)</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue change at constant currency</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">541.6&#160;</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Contract Manufacturing, Royalty and Other Revenue&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue change, as reported</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38.5)</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less&#58; impact of foreign currency translation and hedging gains &#47; losses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.0&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue change at constant currency</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39.5)</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#447260;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">11</font></div></div></div><div id="i805a86fcdf724b4d9a162b5e727cb428_25"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt;text-align:center;text-indent:36pt"><font style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TABLE 4 (continued)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="text-align:center"><font style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GAAP TO NON-GAAP RECONCILIATION</font></div><div style="text-align:center"><font style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FREE CASH FLOW</font></div><div style="text-align:center"><font style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(unaudited, in millions)</font></div><div style="margin-top:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We define free cash flow as net cash provided by (used in) operating activities in the period less capital expenditures made in the period. The following table reconciles net cash provided by (used in) operating activities, a GAAP measure, to free cash flow, a Non-GAAP measure.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"></td><td style="width:63.380%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.440%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.020%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.440%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.020%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flow&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) operating activities</font></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">553.2&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">455.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66.0)</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(953.0)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(439.6)</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(43.4)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</font></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47.6&#160;</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(541.1)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) operating activities</font></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">553.2&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">455.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less&#58; Purchases of property, plant and equipment</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45.9&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Free cash flow</font></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">507.3&#160;</font></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">388.7&#160;</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#447260;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12</font></div></div></div><div id="i805a86fcdf724b4d9a162b5e727cb428_28"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:center;text-indent:36pt"><font style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Use of Non-GAAP Financial Measures </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We supplement our GAAP consolidated financial statements and GAAP financial measures with other financial measures, such as adjusted net income, adjusted diluted earnings per share, revenue growth at constant currency, which excludes the impact of changes in foreign exchange rates and hedging gains or losses, and free cash flow, which is defined as net cash flow from operations less capital expenditures. We believe that these and other Non-GAAP financial measures provide additional insight into the ongoing economics of our business and reflect how we manage our business internally, set operational goals and form the basis of our management incentive programs. Non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our &#8220;Non-GAAP net income attributable to Biogen Inc.&#8221; and &#8220;Non-GAAP earnings per share - Diluted&#8221; financial measures exclude the following items from &#8220;GAAP net income attributable to Biogen Inc.&#8221; and &#8220;GAAP earnings per share - Diluted&#8221;&#58;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:174%;text-decoration:underline">1. Acquisitions and divestitures</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We exclude transaction, integration and certain other costs related to the acquisition and divestiture of businesses  and items associated with the initial consolidation or deconsolidation of variable interest entities. These adjustments include, but are not limited to, the amortization and impairment of intangible assets, charges or credits from the fair value remeasurement of our contingent consideration obligations and losses on assets and liabilities held for sale. </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:174%;text-decoration:underline">2. Restructuring, business transformation and other cost saving initiatives</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We exclude costs associated with our execution of certain strategies and initiatives to streamline operations, achieve targeted cost reductions, rationalize manufacturing facilities or refocus research and development activities. These costs may include employee separation costs, retention bonuses, facility closing and exit costs, asset impairment charges or additional depreciation when the expected useful life of certain assets have been shortened due to changes in anticipated usage and other costs or credits that management believes do not have a direct correlation to our ongoing or future business operations.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:174%;text-decoration:underline">3. (Gain) loss on equity security investments</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We exclude unrealized and realized gains and losses related to our equity security investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:174%;text-decoration:underline">4. Other items</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate other items of income and expense on an individual basis and consider both the quantitative and qualitative aspects of the item, including (i) its size and nature, (ii) whether or not it relates to our ongoing business operations and (iii) whether or not we expect it to occur as part of our normal business on a regular basis. We also include an adjustment to reflect the related tax effect of all reconciling items within our reconciliation of our GAAP to Non-GAAP net income attributable to Biogen Inc. and earnings per share - diluted. </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#447260;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">13</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>biib-20240424.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:31ab756c-268d-47bf-960f-40deff5d63b1,g:9ac60f70-3d0b-4dd0-82a8-03278455582b-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:biib="http://www.biogenidec.com/20240424" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.biogenidec.com/20240424">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20240424_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20240424_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.biogenidec.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>biib-20240424_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:31ab756c-268d-47bf-960f-40deff5d63b1,g:9ac60f70-3d0b-4dd0-82a8-03278455582b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SecurityExchangeName_a9d11303-2022-4317-acdb-b3da8c97113e_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_0356ba77-75b9-40f3-830a-85f551d4ad5e_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_1f766318-48a9-48b5-8bce-f2331588e035_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_3b92aa97-deff-483b-bd5a-7d899857ede0_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_6973b828-121d-4891-b61a-a3eae7b8c859_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_4e6135fb-36ec-4c03-832d-2410c3061da7_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_db82b7f2-4100-402a-a333-980987361f84_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_e16ca3e0-3151-42bb-94e1-f165479cb3e2_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_2bcc3a87-6ffa-4545-9444-2a1e6da1952e_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_342d4e1d-4eab-4935-b277-57669834dbbc_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_6a86ca78-a5d5-4ddc-81c6-031c5ee7b293_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_84e9faad-4a23-49f7-8282-5ae1d3e8569f_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_cb1ac033-48b5-4fad-94a5-0467b88820d8_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_01944a31-10e0-4e3c-9d32-1dfebc61f0b7_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_0c0f5a22-4eef-4db6-9983-954cbe1afd39_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_464710ad-a08c-48e6-851f-3f9c5f3e30b8_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_4b95c38f-a4ef-403c-b97b-4388334fe2dc_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_0f90ee92-49f4-4a24-9452-8b9c72993d90_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_74c35972-1024-4070-87c8-2732014e1051_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_7f3db579-8a5b-4539-a6d2-179886d54714_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_b5e5eedc-e87c-4d4b-9415-d1e4c4a2d889_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_03c167dc-564d-49b0-86f5-0e04bd658638_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_f03099c0-1e84-4564-b4b9-a3031e3c829f_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>biib-20240424_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:31ab756c-268d-47bf-960f-40deff5d63b1,g:9ac60f70-3d0b-4dd0-82a8-03278455582b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biogenidec.com/role/CoverPage" xlink:type="simple" xlink:href="biib-20240424.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_1aed6fdd-639d-4f89-aee0-81f58a9fdfea" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_cb5100f9-e531-4614-8c61-ab215e6a980b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1aed6fdd-639d-4f89-aee0-81f58a9fdfea" xlink:to="loc_dei_DocumentType_cb5100f9-e531-4614-8c61-ab215e6a980b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_b5ac6b55-0313-4f2e-80be-607aa6a32cf1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1aed6fdd-639d-4f89-aee0-81f58a9fdfea" xlink:to="loc_dei_DocumentPeriodEndDate_b5ac6b55-0313-4f2e-80be-607aa6a32cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_f81da5a3-77fc-47e0-bdad-071054b91d3a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1aed6fdd-639d-4f89-aee0-81f58a9fdfea" xlink:to="loc_dei_EntityRegistrantName_f81da5a3-77fc-47e0-bdad-071054b91d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_37419594-4213-48cb-96ba-c434e93d86c8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1aed6fdd-639d-4f89-aee0-81f58a9fdfea" xlink:to="loc_dei_EntityIncorporationStateCountryCode_37419594-4213-48cb-96ba-c434e93d86c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_4002c5bf-29fc-41c0-b3cc-d13d9a2b7193" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1aed6fdd-639d-4f89-aee0-81f58a9fdfea" xlink:to="loc_dei_EntityFileNumber_4002c5bf-29fc-41c0-b3cc-d13d9a2b7193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_3c5ba530-3561-4a54-8953-54dc052615d3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1aed6fdd-639d-4f89-aee0-81f58a9fdfea" xlink:to="loc_dei_EntityTaxIdentificationNumber_3c5ba530-3561-4a54-8953-54dc052615d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_0eb2054e-4697-4eda-9d7a-a68d650e4731" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1aed6fdd-639d-4f89-aee0-81f58a9fdfea" xlink:to="loc_dei_EntityAddressAddressLine1_0eb2054e-4697-4eda-9d7a-a68d650e4731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_88df37a1-5f1c-4ba2-bcb7-f67becc16ccb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1aed6fdd-639d-4f89-aee0-81f58a9fdfea" xlink:to="loc_dei_EntityAddressCityOrTown_88df37a1-5f1c-4ba2-bcb7-f67becc16ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_e1ad6571-bf98-4ff5-9e24-07602aedf88f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1aed6fdd-639d-4f89-aee0-81f58a9fdfea" xlink:to="loc_dei_EntityAddressStateOrProvince_e1ad6571-bf98-4ff5-9e24-07602aedf88f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_1ba56f34-1bda-4cda-a7c8-f2a37201d501" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1aed6fdd-639d-4f89-aee0-81f58a9fdfea" xlink:to="loc_dei_EntityAddressPostalZipCode_1ba56f34-1bda-4cda-a7c8-f2a37201d501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_0280ed29-c652-4a81-90d8-cd6f2c24bfb1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1aed6fdd-639d-4f89-aee0-81f58a9fdfea" xlink:to="loc_dei_CityAreaCode_0280ed29-c652-4a81-90d8-cd6f2c24bfb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_26cfba67-7c10-434b-8414-6094ba05ca71" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1aed6fdd-639d-4f89-aee0-81f58a9fdfea" xlink:to="loc_dei_LocalPhoneNumber_26cfba67-7c10-434b-8414-6094ba05ca71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_142aaca4-b65c-4537-ab9b-2747cbbf8405" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1aed6fdd-639d-4f89-aee0-81f58a9fdfea" xlink:to="loc_dei_WrittenCommunications_142aaca4-b65c-4537-ab9b-2747cbbf8405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_16b23db6-69bb-451c-ba39-80adcf34fc14" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1aed6fdd-639d-4f89-aee0-81f58a9fdfea" xlink:to="loc_dei_SolicitingMaterial_16b23db6-69bb-451c-ba39-80adcf34fc14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_550d17ab-160a-4ae4-807a-f1a03946cf5d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1aed6fdd-639d-4f89-aee0-81f58a9fdfea" xlink:to="loc_dei_PreCommencementTenderOffer_550d17ab-160a-4ae4-807a-f1a03946cf5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_0116bd86-8016-4aa9-849a-102eec763d8c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1aed6fdd-639d-4f89-aee0-81f58a9fdfea" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_0116bd86-8016-4aa9-849a-102eec763d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_9ec606b6-4a0c-4b78-9059-5d1b7f9710c2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1aed6fdd-639d-4f89-aee0-81f58a9fdfea" xlink:to="loc_dei_Security12bTitle_9ec606b6-4a0c-4b78-9059-5d1b7f9710c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_f0cad0cc-8e54-4b55-99ca-60bb9eb22ae5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1aed6fdd-639d-4f89-aee0-81f58a9fdfea" xlink:to="loc_dei_TradingSymbol_f0cad0cc-8e54-4b55-99ca-60bb9eb22ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_ebb77c2d-12fc-43fb-b54d-41325dd25dc6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1aed6fdd-639d-4f89-aee0-81f58a9fdfea" xlink:to="loc_dei_SecurityExchangeName_ebb77c2d-12fc-43fb-b54d-41325dd25dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_6673d352-3865-4624-8a44-9bd01d0737e2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1aed6fdd-639d-4f89-aee0-81f58a9fdfea" xlink:to="loc_dei_EntityEmergingGrowthCompany_6673d352-3865-4624-8a44-9bd01d0737e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_af0b3642-c6cb-47ce-a1f5-aeef46506bac" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1aed6fdd-639d-4f89-aee0-81f58a9fdfea" xlink:to="loc_dei_EntityCentralIndexKey_af0b3642-c6cb-47ce-a1f5-aeef46506bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_ddc96330-90ad-4174-8b0e-d7ea93a96008" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1aed6fdd-639d-4f89-aee0-81f58a9fdfea" xlink:to="loc_dei_AmendmentFlag_ddc96330-90ad-4174-8b0e-d7ea93a96008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>newbiogenlogo.jpg
<TEXT>
begin 644 newbiogenlogo.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  G '8# 2(  A$! Q$!_\0
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M9 IZ<#@[N#U]<OXJ:;>_"[X;_"/PIXNTV6;PK\U[JMO;[1<M,9"[1!CRI5)
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MNJ27DSW5Y:2()8%+!0(^1AL!1SZYQZUU7ASX,>!O".I+J.D>%=,L;Y.4N(X
M73_=)SM_#%%%?&U<97JSG-R:YG=VT7W'UU/"T:4(045[JLKZO[S7U[P+X>\4
M:A97VKZ+9:E>61S;3W,*N\)R&RI(XY /X59\1>%](\7:=]@UO3;;5;+>)/L]
MW&)$W#H<'OR:**Y_:35K2>FWEZ&_LX.^BUW\RWIVG6ND6%O8V5O':V=O&L4,
5$*A4C0# 4 = !1114-MN[+VT1__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139727086690448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>Apr. 24, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr. 24,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIOGEN INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-19311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0112644<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">225 Binney Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">679-2000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0005 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BIIB<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000875045<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M;^0CKX?"I:"LO.MNVPO:&%EE^+1AKP[3,BJFYGW,5K4\N,#)07*/SH[V'/[
M;%HR$O,E"'E77;!KO3_:[AM&I<5Q<J$,'$Z+VS5GX!/V WB_5,J\-^P)M?P'
MP^!_4$L#!!0    ( %LXF%B?H!OPL0(  .(,   -    >&PO<W1Y;&5S+GAM
M;-U7;6O;,!#^*T(_8&YB:N*1&+9 8;"-0O-A7Y58=@1Z\62Y<_KKI[-L)VEU
M9=V'L<VAR=T]NKM'=R>9KEMWDOSAR+DCO9*ZW="C<\W[)&D/1ZY8^\XT7'ND
M,E8QYU5;)VUC.2M;<%(R6=[<9(EB0M-BK3MUIUQ+#J;3;D-O:%*L*Z//EI0&
M@U_*%">/3&[HEDFQMV)8RY20IV!>@N%@I+'$>2I\0Q=@:9\"O @:L!SC**&-
M!6,2,H3O_;C\&3!IK5>%E#/!)0V&8MTPY[C5=UX9%@_&%Q 9Y=VI\0QKRTZ+
MY2T].PP_/LG>V)+;.<V"3J9B+7D%=*RHC_#K3), Z)Q17B@%JXUF X?)8Q1\
MV .7\@%:^*VZBMU7)/3B4PEM(+#52?2$1C&$"0K$OXP68E^$O?VML*01C\9]
M[/QN]*!_[XSC]Y97HA_TOIKS8]$7>'36-/+T08I:*Q[V_LL)BS6;_,C16/'D
ML\&D'+R!6TH>N77B<&GY85FSX[V;IJFO<,[+?Y#SGZUSS36W3%Z2]J/_-U?Y
M+8R3\?1<'-&K SI;"5R$&_H5[E=YYD#VG9!.Z%$[BK+D^L4Y]>$=V_L+_"J^
M7U_RBG72[69P0\_R%UZ*3N7SJGNHR[CJ+'^&^VB1S;>PSR5TR7M>;D?5UOM!
M)%[P6<<'')XC=\,31S"?@,41P+ \& /,)WAA>?ZG_:S0_00,X[:*(BO49X7Z
M!*\8LAT^6)ZX3^Z?^$[S/$VS#*OH=AMEL,7JEF7P%X^&<0,/+ ]D>ENM\6[C
M$_+Z'& ]?6U"L)WBDXCM%*\U(/&Z@4>>Q[N-Y0$/K O8[$#^>!Z8J;A/FD)7
M,6[8"<:1/,<0F,7XC&894IT,/O'^8*<D3?,\C@ 69Y"F& *G$4<P!L !0])T
M> \^>Q\ETWLJ.?]74_P$4$L#!!0    ( %LXF%B7BKL<P    !,"   +
M7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_
MK]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?2
M0$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-
MTG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z
M6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ 6SB86!E%%?4W 0
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M)H]:1NO<2KGW\$JV''..?[3\ 5!+ P04    " !;.)A8)!Z;HJT   #X 0
M&@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4 -5"I
M0P5,75@K+A %\R,2$L6N"K<OA0&0.G1ALIXM?^_)3I]H%'=NH+;S)$9K!LID
MR^SO *1;M(HNSN,P3VH7K.)9A@:\TKUJ$)(HND'8,V2>[IFBG#S^0W1UW6E\
M./VR./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@;6E6
M?;!/3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @ 6SB86&60>9(9 0
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M<',O87!P+GAM;%!+ 0(4 Q0    ( %LXF%A17!;^[P   "L"   1
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M96QS+RYR96QS4$L! A0#%     @ 6SB86!E%%?4W 0  )P(   \
M     ( !0Q   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( %LXF%@D'INB
MK0   /@!   :              "  :<1  !X;"]?<F5L<R]W;W)K8F]O:RYX
M;6PN<F5L<U!+ 0(4 Q0    ( %LXF%AED'F2&0$  ,\#   3
M  "  8P2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  -83
$      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="biib-20240424.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="biib-20240424.htm">biib-20240424.htm</File>
    <File>biib-20240424.xsd</File>
    <File>biib-20240424_lab.xml</File>
    <File>biib-20240424_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "biib-20240424.htm": {
   "nsprefix": "biib",
   "nsuri": "http://www.biogenidec.com/20240424",
   "dts": {
    "inline": {
     "local": [
      "biib-20240424.htm"
     ]
    },
    "schema": {
     "local": [
      "biib-20240424.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "biib-20240424_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "biib-20240424_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://www.biogenidec.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240424.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20240424.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0000875045-24-000012-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000875045-24-000012-xbrl.zip
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M?/:__V97K?W%?[<]E%N3O-LX^O??ZHY=VY=$L9 -^W'$2*3]PQZZRC!!^T\
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M)3N=BTF.X+WAI'(\.PF 1+U$1%SV<8:(IOK<XXHT&J:M!]=U['Q?*;0!4,B
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M1DN,ASTMM66N7_1'7(7<7;R]1?W-[(5X5]!P=O3T1?O2/AY_=O0W4$L#!!0
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MB\;>=_YU8JL>>V9.R,@'32F1MF7;ENM\>E^NGXO]FY8=HO; G<(MU:*X-H3
MQ/624JF^B;I2@H(V X6!YYJA$0RA83)4FSYLK"10'K@!M>=<KGXLD)>>93,!
M+G? /!J@HK4<P^TSH [V0M3B%-W,OTW3/PKH]AEUX&(GM(G5AZ4],Z[)8?O
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M.99A&]PD?,"[+_\G=>!]GJI82E]W'=Z=*[1QY'=PMVD01 $71/\RQ;E41"1
M33,Q)TY-CSPT?Q^'S3'H(;*;_N?="L^%ML9&P$S?"ID/S@]:0:L7=PRYA "4
M"+T!@/3*CNV3@P+02?7S1PF>;<&3/962ESO7=$1SH^"F"PH3TFJYU%U*=<>J
M*X<"!J P5F]ZK%!0=ZR#<@@"GC?3SJ6VD=IF?:*95\(N-<Y"65N2LI9#09=Z
MMR8UCM0X26F<7WA%P)R"B*F^T=D8\70GZ<C)YE4%Q=%7:!L\;= !"[^R9BY
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MG6*29H;/Q5!X/N+AAA^F4U(+1"MJ^F[C>#N%R8YMWV4PN6(&Z[?!@8O 4IH
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MX*U=E]KB00#C/G]OF_K6\%WB>9SR /WP#[)3G%U1ENX1R !Q%V^1!&Z!.&Y
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M,#(T,#0R-"YX<V102P$"% ,4    " !;.)A88%9ZZ"4*  !]50  %0
M        @ %B$0  8FEI8BTR,#(T,#0R-%]L86(N>&UL4$L! A0#%     @
M6SB86)V=I1.N!@  [C   !4              ( !NAL  &)I:6(M,C R-# T
M,C1?<')E+GAM;%!+ 0(4 Q0    ( %LXF%C +TOU6E8  +RD!0 >
M      "  9LB  !E>&AI8FET.3DQ+7$Q,C R-'!R97-S<F5L92YH=&U02P4&
2      4 !0!0 0  ,7D

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>biib-20240424_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="biib-20240424.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2024-04-24</startDate>
            <endDate>2024-04-24</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-21">0000875045</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-22">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-04-24</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">BIOGEN INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">0-19311</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">33-0112644</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">225 Binney Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">679-2000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, $0.0005 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">BIIB</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
